Recent FDA approval of nirsevimab and clesrovimab have transformed RSV prevention in infants, prompting new recommendations from the CDC and AAP and replacing the long-standing role of palivizumab.
Rylee Johns, PharmD Candidate
Advertisement
Articles by Rylee Johns, PharmD Candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis
2
FDA Approves 10% IVIG Formulation For Adults With Primary Humoral Immunodeficiency
3
Improved Outcomes in NDTE Multiple Myeloma With Belantamab Mafodotin Plus VRd Following 2 Years of Maintenance
4
Annual Pharmacy Technician Convention Brings Educational Opportunities, Leadership Development
5
